Phaseline

Companies › Sedana Medical

Sedana Medical: clinical trials, targets and expected readouts

1 active drug program in 7 registered trials: 4 Phase 3, 2 Phase 4, 1 Phase 2; Infectious disease, Metabolic and endocrine, Other, Psychiatry.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Isoflurane
Glycine receptor (alpha-1/beta) positive modulator; GABA-A receptor; anion channel positive allosteric modulator; Potassium channel subfamily K member 10 opener
GLRA1, GLRB, GABRA1, GABRB2, GABRG2Phase 3Post-Intensive Care Syndrome; Diabete Mellitus; Sedation; Prevention of Delirium …–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06809218IsofluranePhase 3Post-Intensive Care SyndromePsychiatryNov 2024
NCT04341350IsofluranePhase 3Prevention of DeliriumOtherSep 2025
NCT07496593IsofluranePhase 4Diabete MellitusMetabolic and endocrineDec 2026
NCT05867472IsofluranePhase 3Intensive Care Units, PediatricRespiratoryDec 2026
NCT07000526IsofluranePhase 4SedationOtherMar 2027
NCT04415060IsofluranePhase 3Covid19Infectious diseaseJun 2027
NCT06014138IsofluranePhase 2Acute Respiratory Distress SyndromeRespiratoryJul 2027

Targets

GLRA1 (1) GLRB (1) GABRA1 (1) GABRB2 (1) GABRG2 (1)

Companies with the same targets

Ono Pharmaceutical Lipocine UCB Biopharma SRL Haisco Pharmaceutical Group SK Life Science Acacia Pharma Pharmasoft NeuroRx Seaport Therapeutics Neurodawn Pharmaceutical

Companies built like this

Acacia Pharma Soleno Therapeutics Tiohundra BioVersys SAS Biotechnology Institute IMASD

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.